Elon Musk’s brain-tech company, Neuralink, has successfully raised $650 million in its latest funding round, coinciding with the launch of clinical trials for its brain implant devices. Prominent investors such as ARK Invest, DFJ Growth, Founders Fund, G42, Human Capital, Lightspeed, QIA, Sequoia Capital, Thrive Capital, Valor Equity Partners, and Vy Capital participated in the round.

Neuralink stated that the funding will help expand access to its technology, aiming to restore independence for individuals with critical medical needs and advance the frontiers of brain-computer interface innovation. Currently, five patients with severe paralysis are using Neuralink’s device to control both digital and physical systems purely through thought.

The U.S. FDA recently granted “breakthrough device” status to Neuralink’s speech-restoration technology—a designation already earned by its vision-restoration device last year. This classification accelerates the regulatory process to bring such innovations to patients and providers more quickly.

Meanwhile, Elon Musk is stepping away from his advisory role to former U.S. President Donald Trump to refocus on his ventures including Tesla, SpaceX, xAI, Neuralink, and the social platform X. In related news, reports indicate that Morgan Stanley is seeking a $5 billion debt deal for Musk’s AI startup, xAI, which is reportedly targeting a $113 billion valuation through a $300 million share sale.

Previously, Semafor reported that Neuralink had secured $600 million, valuing the firm at $9 billion, even before this latest capital infusion.